Article

2014 Giants of Cancer Care Nominations Now Open

Author(s):

Giants of Cancer Care is now accepting nominations for the 2014 awards program.

PLAINSBORO, N.J. — Feb. 14, 2014 – Giants of Cancer Care, presented by OncLive, is now accepting nominations for the 2014 awards program. This will mark the second annual Giants of Cancer Care awards, which last year honored 12 of the top pioneers and innovators in oncology.

Nominations are free and can be submitted via the Giants of Cancer Care’s website: giants.onclive.com. The deadline for nominations is April 1, 2014.

The Giants of Cancer Care initiative recognizes and celebrates individuals who have achieved landmark success within the field of oncology. This program is presented by OncLive, home of Oncology & Biotech News, OncologyLive, and Urologists in Cancer Care, Oncology Nursing News, and Contemporary Oncology.

Giants will be named in 11 ‘tumor type’ categories including breast cancer, lung cancer, melanoma and prostate cancer, as well as five ‘specialty’ categories.

The tumor type categories include:

  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Genetics
  • Head and Neck Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Myeloma
  • Prostate Cancer

The specialty areas include:

  • Community Outreach: Awarded to a person who donates his or her time and resources to improve the community in which he or she serves as it relates to improving or prolonging the lives of those with cancer
  • Drug Development: Awarded to an oncologist who has successfully paved the way for new, impactful medication to reach the patient population
  • Education: Awarded to an oncologist who champions the education of others in the field
  • Scientific Advances: Awarded to an oncologist who has successfully leveraged technology to advance cancer care standards
  • Supportive Care: Awarded to an oncologist who excels in providing supportive care and demonstrates innovation in relieving patient pain and discomfort

Visit giants.onclive.com for a full list of categories.

“To say their work is an uphill battle is an understatement, yet I frequently meet oncologists whose drive and grace working in the field are unparalleled,” said Michael J. Hennessy, OncLive Chairman and CEO. “I am devoted to advancing this cause as a result of my immense passion and respect for these physicians.”

The Giants of Cancer Care program is judged by a 29-member Advisory Panel of eminent oncologists and leaders in the field, who consider a nominee’s body of work, including clinical impacts, significant contributions and overall accomplishments. The Advisory Panel is chaired by Dr. Hope Rugo, a medical oncologist and hematologist specializing in breast cancer research and treatment. Currently, Dr. Rugo serves as the Director of the Breast Oncology and Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center.

The 2014 Giants of Cancer Care program winners will be announced in May 2014 and recognized in OncologyLive.

To learn more about the Giants of Cancer Care and to view the 2013 class of Giants, visit giants.onclive.com.

###

About OncLive®

OncLive.com is the official information hub for Intellisphere’s Oncology Specialty Group, which publishes OncologyLive, Oncology & Biotech News, Oncology Nursing News, Urologists in Cancer Care, and Contemporary Oncology, and presents the Giants of Cancer Care program. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, and a leading provider of healthcare publishing, research, and education. To learn more, please visit www.OncLive.com.

Media Contact:

Mike Gross

For OncLive

267-932-8760 ext. 310

mike@hornercom.com

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
3 experts are featured in this series.
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video